Which regulatory submission is typically required in the US BEFORE initiating a Phase I clinical trial with a new investigational drug?
-
A
New Drug Application (NDA)
-
B
Investigational New Drug (IND) application
-
C
Biologics License Application (BLA)
-
D
Abbreviated New Drug Application (ANDA)